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ABSTRACT
In humans, more than 30,000 chimeric transcripts originating from 23,686 genes have been identified. The mechanisms and
association of chimeric transcripts arising from chromosomal rearrangements with cancer are well established, but much
remains unknown regarding the biogenesis and importance of other chimeric transcripts that arise from nongenomic alterations.
Recently, a SLC45A3–ELK4 chimera has been shown to be androgen-regulated, and is overexpressed in metastatic or high-grade
prostate tumors relative to local prostate cancers. Here, we characterize the expression of a KLK4 cis sense–antisense chimeric
transcript, and show other examples in prostate cancer. Using non-protein-coding microarray analyses, we initially identified an
androgen-regulated antisense transcript within the 39 untranslated region of the KLK4 gene in LNCaP cells. The KLK4 cis-NAT
was validated by strand-specific linker-mediated RT-PCR and Northern blotting. Characterization of the KLK4 cis-NAT by 59 and
39 rapid amplification of cDNA ends (RACE) revealed that this transcript forms multiple fusions with the KLK4 sense transcript.
Lack of KLK4 antisense promoter activity using reporter assays suggests that these transcripts are unlikely to arise from a trans-
splicing mechanism. 59 RACE and analyses of deep sequencing data from LNCaP cells treated ±androgens revealed six high-
confidence sense–antisense chimeras of which three were supported by the cDNA databases. In this study, we have shown
complex gene expression at the KLK4 locus that might be a hallmark of cis sense–antisense chimeric transcription.
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INTRODUCTION
The Kallikrein-related peptidase 4 (KLK4) gene comprises
five coding exons and was concomitantly cloned by three
laboratories (Nelson et al. 1999; Stephenson et al. 1999; Yousef
et al. 1999; Hu et al. 2000).KLK4 is located on 19q13.4, where
it is colocalized with 14 other members of the kallikrein-
related peptidase gene family, which includes the KLK3/PSA
gene (Harvey et al. 2000; Yousef et al. 2000). KLK4 gene
expression is predominantly localized to the prostate, al-
though modest-to-low levels have been detected in other
tissues including but not limited to the breast, ovary, endo-
metrium, salivary gland, lung, adrenal gland, colon, trachea,
brain, testis, spinal cord, thyroid, skin, and kidney (Nelson
et al. 1999; Yousef et al. 1999; Shaw and Diamandis 2007).
The known biological role of KLK4 is derived from
porcine studies that show that KLK4 is important in
degradation of enamel matrix proteins during tooth mat-
uration (Hu et al. 2007). The role of KLK4 in the prostate is
less well defined, although studies have shown higher levels
of KLK4 in malignant prostate cells compared to benign
cells (Veveris-Lowe et al. 2005; Klokk et al. 2007). Further-
more, prostate cancer cells (PC-3 and DU145) transfected
with KLK4 have increased cellular migration, proliferation,
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and colony formation (Veveris-Lowe et al. 2005; Klokk
et al. 2007). KLK4 is also thought to be important in
mediating migration of prostate cancer cells toward bone,
a common site of prostate cancer metastasis (Gao et al.
2007). The role of KLK4 in prostate biology is thought to
be mediated in part through activation of the PAR-1 and
PAR-2 signaling pathways (Ramsay et al. 2008), although
the precise mechanisms and importance in prostate cancer
remain to be identified.
Inprostate cancer cells,KLK4 is up-regulatedby the andro-
gen receptor (AR) signaling axis (Nelson et al. 1999; Yousef
et al. 1999; Korkmaz et al. 2001; Lai et al. 2009), which is an
important pathway in prostate cancer progression. KLK4
transcripts using alternative transcription start sites (TSSs)
(Hu et al. 2000; Korkmaz et al. 2001; Lai et al. 2009) and other
insertion/deletion variants have been described (Dong et al.
2001, 2005; Korkmaz et al. 2001; Kurlender et al. 2005).
Transcription studies have identified many chimeric
transcripts (Kapranov et al. 2005; Akiva et al. 2006; Parra
et al. 2006; Denoeud et al. 2007), suggesting that transcrip-
tion and splicing events are more complex than previously
recognized. Although the mechanisms and association of
chimeric transcripts arising from chromosomal rearrange-
ments with cancer are well established (Tomlins et al. 2005;
Soda et al. 2007), much remains to be known regarding the
biogenesis and importance of other chimeric transcripts
that arise from nongenomic alterations. In humans, 31,005
nonchromosomal rearrangement chimeric transcripts orig-
inating from 23,686 genes (49% of the genome) have been
identified, suggesting that chimeric gene expression occurs
on a global scale (Li et al. 2009). Although few chimeric
transcripts have been well characterized, an SLC45A3–ELK4
chimera has been shown to be androgen-regulated in
prostate cells and is overexpressed in metastatic or high-
grade prostate tumors relative to benign prostate cancer
cells (Maher et al. 2009; Rickman et al. 2009).
Currently, three models have been proposed for chimeric
transcripts that arise from events other than genomic
rearrangements. The trans-splicing model proposes that
independently transcribed RNAs are spliced together using
the same machinery as cis-splicing due to the presence of
GU-AGmotifs at the junctions of the two chimeras (Horiuchi
and Aigaki 2006). The transcriptional slippage model sug-
gests that transcribed RNAs dissociate from the RNA poly-
merase II (Pol II) complex, then hybridizes with another
DNA template at a different locus using short homologous
sequences, where transcription resumes (Li et al. 2009). The
third model is described by the RNA-dependent RNA poly-
merase (RdRP) activity of human telomerase reverse tran-
scriptase (TERT) transcribing the antisense RNA using the
sense RNA as template (Maida et al. 2009).
In this study, we initially identified a novel androgen-
regulated KLK4 antisense transcript by high-throughput
microarray analysis designed to detect novel androgen-
regulated transcription. Sequencing of this transcript revealed
that this KLK4 antisense transcript forms a chimera with
the sense transcript. Data from this study suggest that the
transcriptional slippagemechanismmight mediate formation
of the KLK4 sense–antisense chimera due to the lack of KLK4
antisense promoter activity, and the imperfect nature of the
sense–antisense chimeras. We also show other examples of
sense–antisense chimeras in a human LNCaP RNA-seq data
set, and by 59 rapid amplification of cDNAends (RACE) using
unidirectional PCR to target cis sense–antisense chimeras.
RESULTS
Identification and validation of the KLK4 antisense
transcript
Using the Agilent 244K microarray, a transcript located
antisense to the KLK4 39 untranslated region (UTR) (CGH
probe A_14_P104372) was found to be 3.4-fold up-regulated
in synthetic androgen (1 nM R1881) treated cells at 48 h
relative to vehicle control–treated cells (Fig. 1A). To over-
come the nonspecificity of RT-PCR in validating the KLK4
antisense transcript due to RNA self-priming in reverse
FIGURE 1. Validation of the KLK4 antisense transcript. (A) A micro-
array probe (red box with white arrowhead) detected a 3.38-fold
androgen up-regulated KLK4 antisense transcript (pink box) in LNCaP
prostate cancer cells. Primers used in subsequent figures are shown
relative to the classical KLK4 sense transcript, which is encoded by five
exons (blue boxes). Dotted lines represent unknown antisense se-
quences. (B) Diagram of the RT-PCR approach taken to differentiate
overlapping sense antisense transcripts. (C) Validation of the KLK4
sense and antisense transcripts using strand-specific primers conjugated
to synthetic linker sequences. PCR was carried out at 30 cycles using
linker 1 (L1) and linker 2 (L2) primers, and the specified KLK4 primer.
Expression of a KLK4 sense–antisense transcript
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transcription (Supplemental Fig. 1A) and the co-localization
of both sense and antisense transcripts to the same genomic
locus, a synthetic linker sequence conjugated to the strand-
specific primer was used in the RT reaction. The strand of
the RNA can then be determined as products only amplify
from cDNA synthesized from strand-specific linker primers
due to the use of a linker-only primer, and a gene-specific
primer in subsequent PCRs (Fig. 1B). Consequently, cDNA
generated from random oligonucleotides or RNA self-
priming cannot be amplified in PCR as these cDNAs lack
linker sequences for PCR. Using this approach, both the
KLK4 sense and antisense transcripts were detected in 1 nM
R1881-treated LNCaP cells (Fig. 1C). The strand specificity
of this approach is shown by the amplification of both KLK4
sense and antisense transcripts from cDNA synthesized from
strand-specific linker primers, and not from cDNA synthe-
sized using random hexameric oligonucleotides (Fig. 1C;
Supplemental Fig. 1B).
The 59 end of the KLK4 antisense transcript forms
a chimera with the KLK4 sense transcript
59 RNA ligase–mediated (RLM)-RACE was carried out to
identify the 59 end of the KLK4 antisense transcript.
Initially, two bands of 608 bp and 541 bp were detected
by PCR from RLM-RACE cDNA using an internal primer
within the CGH microarray probe sequence that was
initially used to identify the KLK4 antisense transcript
(Fig. 2A). RNA was extracted from LNCaP cells treated
with R1881 for 24 h. However, the TSS of the KLK4
chimeras was mapped to exon 2 sense (Fig. 2B). As shown
in Figure 2B and Supplemental Figure 2A, the point of
fusion between the sense and antisense transcripts occurs
prior to the end of exon 3 (sense) and within the MSR1
repeat of exon 5 (antisense). Other chimeras were also
detected by 59 RACE, including an exon 2 deleted but
partial intron 2 and 3 retained variant, and an exon 3
deleted variant (Fig. 2C). The strands of the chimera were
determined using the 59-RACE adapter oligonucleotide as
reference. These products are unlikely to be ligation
artifacts from 59 RACE as they were also detected in cDNA
generated from nonligated RNA, and PCR using KLK4
primers (Supplemental Fig. 2B, upper panel). Furthermore,
the observation of these products in other prostate cancer
cell lines (Supplemental Fig. 2B, lower panel) and the
absence in genomic DNA (data not shown) suggest that
these chimeras are not the result of chromosomal DNA
rearrangements.
FIGURE 2. Mapping of the KLK4 antisense transcription start site (TSS) in LNCaP cells. (A) Two transcripts were initially identified for the
KLK4 antisense transcript by 59 RLM-RACE. (B) Exon usage of the sense–antisense chimeric transcripts identified by 59 RLM-RACE. Also shown
is the location and direction of the internal primer (Ex5S-2) used in 59 RACE. (C) BLAT results of other sense–antisense variants identified by 59
RACE.
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The 39 end of the KLK4 antisense transcript extends
to exon 2 and forms a secondary fusion point
with a sense transcript
39 RACE was carried out to identify the 39 end of the KLK4
antisense transcript, and PCR was performed using an
internal primer sequence that is located within the CGH
probe. One band of 778 bp in size was detected (Fig. 3A).
The intron and exon usage of this chimeric transcript is
shown in Figure 3B and Supplemental Figure 2C. The MSR1
repeat was not found in this transcript, but was detected in
other 39-RACE products using different combinations of
internal and external PCR primers (Fig. 3C). Interestingly,
exon 4 was present in all 39-RACE transcripts and not in any
of the 59-RACE transcripts, suggesting that these amplicons
are not RT second-strand artifacts (Mader et al. 2001;
Zaphiropoulos 2002; Cocquet et al. 2006; Roy and Irimia
2008). Furthermore, the 59 and 39 chimeric transcripts are
unlikely to be the result of sense–antisense cDNA hybrid-
ization artifacts in the PCR as this would result in the
identification of the same transcripts in 59 and 39 RACE.
Northern blot analysis targeting the KLK4 antisense detected
an androgen-regulated transcript of z1.5 kb, which would
correspond to the size of a transcript that comprises both
sequences from 59- and 39-RACE products (Fig. 3D). This
potential transcript is shown in Figure 3E. The strands of the
FIGURE 3. Mapping of the 39 end of the KLK4 antisense transcript in LNCaP cells. (A) One transcript of 778 bp was initially detected by 39
RACE. (B) Diagram of the exon and intron usage of the 39-RACE product. The arrow represents the location and direction of the internal KLK4
primer (Ex5AS-1) used in 39 RACE. (D) BLAT results of other sense–antisense chimeras identified in 39 RACE. (E) Northern blot targeting the
antisense transcript detects an z1.5-kb transcript in cells treated with androgens (R1881) but not in mock-treated cells (ethanol). (F) Diagram
showing the potential exon (numbered boxes) and intron (Int2) usage of a transcript comprising both 59- and 39-RACE sequences.
Expression of a KLK4 sense–antisense transcript
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39-RACE chimeras were determined using the genomic
position of the oligo(dT) primers as reference.
The KLK4 locus is transcriptionally complex
and encodes other trans-chimeras
39 RACE using primers targeting exon 2 sense that would
detect the classical KLK4 transcript were used to further
understand gene transcription at the KLK4 locus. Of the
three more readily detectable transcripts, one represented
the classical KLK4 transcript (Fig. 4, upper panel), one was
a premature truncated variant using a polyadenylation
signal in intron 4 (Fig. 4, middle panel), and the third
was a KLK4–KLP1 chimera (Fig. 4, lower panel).
The KLK4 antisense transcript extends past the MSR1
repeat, but the antisense promoter is transcriptionally
inactive
PCR using linker-primed cDNA revealed that the KLK4
sense transcript extends up to 760 bp downstream from the
MSR1 repeat in LNCaP cells, and that the antisense
transcript starts within 234 bp to 759 bp after the
MSR1 repeat (Supplemental Fig. 3). The extension of the
KLK4 antisense transcript past the MSR1 repeat suggested
that the antisense transcript may be independently tran-
scribed, and that the antisense promoter might be tran-
scriptionally active. In silico analyses of the KLK4 antisense
promoter showed a high concentration of retrotransposon
elements (LINEs and SINEs), as well as a cluster of
predicted Sp1 and TSSs between 1883 bp and 2285
bp from the potential end of the antisense transcript (Fig.
5A). As such, three promoter deletion constructs for the
KLK4 antisense promoter were synthesized and tested for
transcriptional activity in 22Rv1 cells (Fig. 5A). A construct
(K4.2875-Luc) encompassing 2875 bp of promoter for the
sense–antisense chimeras identified in 59 RACE was also
used to compare promoter activities. The PSA promoter
and enhancer (PSA-5.8-A-Luc) was used as a positive
control. Figure 5B shows that the KLK4 antisense promoter
spanning 3357 bp upstream of the potential start site of
the antisense transcript is transcriptionally inactive. The
KLK4 sense promoter for the 59-RACE transcript was
transcriptionally active (Fig. 4B).
Analysis of other MSR1 genes and deep sequencing
tags identifies various loci that produce
sense–antisense chimeras
We hypothesized that the MSR1 repeat is important in
mediating expression of the KLK4 chimera, as this is the
point of fusion between the sense and antisense transcripts.
Consequently, 59 RACE was carried out using primers that
would detect sense–antisense chimeric transcripts for pros-
tate expressed genes that harbor theMSR1 repeat. Of the five
genes tested (KLK3/PSA,KLK14,OSCAR, ATPBD3, ISOC2),
a chimerawas found for the ISOC2 gene (Fig. 6A).We further
investigated the prevalence of sense–antisense chimeric
transcripts by analyzing recently published strand-specific
RNA-seq data from prostate cancer cells (LNCaP) after DHT
FIGURE 4. Further analysis of gene transcription at the KLK4 locus. Shown are the BLAT results from 39 RACE using primers targeting the sense
transcript. The three more readily detected transcripts include the classical KLK4 transcript, a premature intron 4 truncated transcript that is
already in the cDNA databases, and a KLK4–KLP1 chimera.
Lai et al.
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or mock treatment (Li et al. 2008). These strand-specific tags
have been stringently filtered to omit artifacts of strand
switching by reverse transcriptase during cDNA library
preparation (Perocchi et al. 2007) and therefore provide an
amenable data set for identifying chimeric transcripts.
The frequency distribution of tags that mapped to chi-
meric junctions increased as a function of distance to the
junction (Fig. 6B). The increasedmapping frequency relative
to the exon junction is likely to reflect the increasing likeli-
hood of tags mapping by chance; therefore, we omitted any
tags that did not overlap either exon by at least 8 nt. This
minimum threshold was empirically determined from a
background of random interchromosomal splice junctions
(see Materials and Methods). Using this approach, we
identified six novel chimeric sense–antisense splice events
of which three were supported by chimeric cDNA transcripts
(Fig. 6C). Given the stringent requirements imposed by tag
size (33-mers), sequence depth, exact mapping require-
ments, and restriction to well-annotated canonical splice
junctions, it is likely that these events represent a small
fraction of sense–antisense chimeric events.
DISCUSSION
In this study, we report the expression of a KLK4 antisense
transcript that forms chimeras with the KLK4 sense
transcript in prostate cancer cells. The KLK4 antisense
transcript was initially identified in androgen-treated pros-
tate cancer cells (LNCaP) using CGH arrays to detect novel
transcription randomly across the human genome. The
CGH probe detecting the KLK4 antisense transcript was
adjacent to an MSR1 repetitive sequence located within
exon 5. We have validated the KLK4 antisense transcript
using Northern blotting and a linker-mediated RT-PCR
approach (Moseley et al. 2006) due to the confounding
effects of RNA self-priming in RT-PCR (Haddad et al.
2007).
We then carried out 59 RACE to characterize the TSS, as
known sequence data for the KLK4 antisense transcript was
limited to 53 bp from the CGH probe. Results from the 59-
RACE experiments and subsequent unidirectional PCRs
show that the KLK4 antisense transcript forms a non-
genomic rearrangement chimera with KLK4 sense. The
KLK4 chimera starts in exon 2 sense, similar to previous
observations reporting that the exon 2 TSSs are more active
for the classical KLK4 sense transcript (Nelson et al. 1999;
Korkmaz et al. 2001; Lai et al. 2009). Sequencing results
from 39-RACE products revealed that the 39 end of the
KLK4 antisense transcript formed a secondary fusion point
with the classical KLK4 sense transcript.
We suggest that the 59- and 39-RACE chimeras form one
transcript, as there were overlaps between the primers used
in 59 and 39 RACE. Indeed, our Northern blot analyses
targeting the KLK4 antisense transcript identified an
androgen-regulated transcript of z1.5 kb that would
correlate with a transcript comprising both the 59- and
39-RACE transcripts. Furthermore, a recent genome-wide
study of chimeric transcripts revealed that 2% of chimeric
transcripts arise from multiple fusions (Li et al. 2009). The
transcript identified in the Northern blot was lowly
expressed and only detected after long exposure. Of note,
part of the predicted 39 UTR (Nelson et al. 1999), including
the proposed polyadenylation signal, was, in fact, detected
in our 39 RACE chimeric transcripts. Interestingly, our 39
RACE targeting the KLK4 sense transcript showed that the
KLK4 locus is transcriptionally complex and produces
a truncated transcript that utilizes a polyadenylation signal
within intron 4, as well as a trans-chimeric transcript with
the next KLK gene (KLIP1). It is tempting to speculate
whether such complexities at particular loci are reflective of
sense–antisense transcription.
Our identification of a sense–antisense transcript for the
ISOC2 gene that also harbors the MSR1 repeat suggests that
MSR1 might be important in mediating formation of cis
sense–antisense transcripts. Furthermore, our detection of
six high-confidence sense–antisense deep sequencing tags,
three of which are confirmed by cDNA databases, from
LNCaP cells suggest that the sense–antisense event at the
KLK4 locus is not a unique phenomenon.
Currently, there are three models that describe the forma-
tion of chimeric transcripts. However, both the trans-splicing
FIGURE 5. Assessing for basal promoter activity of the KLK4
antisense transcript for evidence of independent KLK4 antisense
transcription. (A) Diagram showing retrotransposon elements (SINE
and LINE) and a cluster of predicted sp1 and transcription start sites
(TSS) located within the putative antisense promoter. Also shown are
the locations of the three inserts used in luciferase reporter assays.
The nucleic acid positions are relative to the reverse primer used
to generate the promoter constructs. (B) Assessing basal promoter
activity of the antisense promoter using reporter assays. Data are
represented as SEM from three independent experiments that were
each carried out in quadruplicate. Data were normalized to pGL3-
Basic activity.
Expression of a KLK4 sense–antisense transcript
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and RNA-dependent RNA polymerase (RdRP) activity mod-
els have limitations in describing transcripts that are similar
to the KLK4 cis sense–antisense chimeras described in this
study. The trans-splicing model (Horiuchi and Aigaki 2006)
would require an active promoter for an independently
transcribed antisense transcript, which we have failed to
detect for KLK4. The RdRP model (Maida et al. 2009) is
limited in describing the KLK4 chimeras in that many of the
transcripts are not perfect sense–antisense chimeras, which is
also supportive of our hypothesis that these transcripts are
not experimental artifacts. Furthermore, the RdRP model
would require that the antisense transcript is first transcribed
in order to provide a template for the sense sequence for the
59-RACE products. The transcriptional slippage model (Li
et al. 2009) at this stage best reflects the cis sense–antisense
chimeras detected for KLK4 in this study, due to the presence
of direct repeats of short homologous sequences at the sense–
antisense junctions (data not shown). However, this requires
that transcription of KLK4 sense by Pol II would need to
either (1) stop then continue transcription in the opposite
direction using the antisense strand as template; or (2) use
the antisense strand from the other chromosome 19 to
continue transcription in the same direction.
There are many interesting aspects to chimeric gene
transcription. Particularly, the question of whether chime-
ric transcripts represent normal or aberrant gene transcrip-
tion is one of great importance. For example, if chimeric
transcripts were the result of dysregulation of normal
transcription and/or splicing processes, then it would be
valuable to understand the mechanisms that mediate these
events. Furthermore, global higher expression of chimeric
transcripts may reflect an ‘‘unhappy cell’’ and consequently
FIGURE 6. Genome-wide identification of sense–antisense chimeric splice events. (A) Identification of a cis sense–antisense transcript in another
MSR1 gene (ISOC2) gene by 59 RACE. (B) Frequency distribution of LNCaP mock- (left) and DHT- (right) treated RNA-seq tags mapping across
sense–antisense chimeric exon–exon junctions. (Red bars) Frequencies of sense–antisense chimeric exon–exon junctions (RefSeq exon paired with
antisense mRNA/EST exon within 10 kb); (blue bars) frequencies of background chimeric exon–exon junction mappings (RefSeq exon paired
with random mRNA/EST exon). Informative tags (indicated) were defined within regions where no background mapping (i.e., mapping by
chance) occurred. (C) Three genes (dark blue) identified from RNA-seq analysis as sharing exon–exon junctions with antisense transcripts (light
blue) with corroborating cDNA transcripts (black). Transcriptional direction and splice junctions are indicated.
Lai et al.
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be used as a diagnostic and/or prognostic marker for
complex diseases such as cancer that are the result of the
accumulation of many genetic and epigenetic events.
Conversely, chimeric gene transcription and/or splicing
may simply reflect nature’s maximization of the coding
potential of exons and promoters as highlighted in a recent
review (Gingeras 2009).
Regardless of whether chimeric transcripts are indicative
of normal physiology or pathophysiology, the implications
for chimeric transcription/splicing are far reaching. For
example, genome-wide single nucleotide polymorphism
(SNP) association studies will be confounded by the fact
that an SNP at one locus may now have a phenotypic effect
on a transcript originating from a distant locus, or possibly
at many loci. Second, our understanding of the factors that
mediate gene transcription will be redefined, as downstream
exons of chimeric transcripts may now co-opt promoters
from upstream exons from a different locus. This is
highlighted by the adoption of the androgen-responsive
SLC45A3 promoter by the ETS transcription factor ELK4
(Maher et al. 2009; Rickman et al. 2009). Importantly, the
SLC45A3–ELK4 chimera is associated with high-grade and
metastatic prostate cancers relative to benign prostate
cancers (Maher et al. 2009; Rickman et al. 2009). Indeed,
these aspects may now confer biological significance to
chimeric transcripts even when they are lowly expressed. On
a practical level, cis sense–antisense chimeras will confound
results from experiments such as in situ hybridization that
often use the antisense strand as a negative control.
In conclusion, we have identified a novel KLK4 sense–
antisense chimera that to our knowledge is one of few
(Bartsch et al. 2004; Maida et al. 2009) well-characterized
reports of endogenous cis sense–antisense chimeric tran-
scripts. Open reading frame analysis (data not shown)
suggests that the KLK4 chimera is unlikely to encode
a secreted and proteolytic active serine peptidase due to the
loss of the pre-pro domain in this variant, and the catalytic
serine residue located within exon 5. Future inhibition
studies that selectively target the KLK4 chimera will further
our understanding of the biological significance of this
transcript, especially given the high concentration of MSR1
on chromosome 19 and within the KLK locus (Das et al.
1987), and the potential of these chimeras to be processed
into short double-stranded RNA. Preliminary studies of the
SLC45A3–ELK4 chimera (Maher et al. 2009; Rickman et al.
2009) show potential for other chimeric transcripts to
function as a prognostic marker for prostate cancer.
MATERIALS AND METHODS
Cell culture
All cell lines used were obtained from the American Type Culture
Collection (ATCC). LNCaP, 22Rv1, DU145, and PC-3 were
maintained in RPMI 1640 media (Invitrogen) supplemented with
10% fetal calf serum (FCS) (Invitrogen). RWPE-1 cells were
grown in keratinocyte serum-free medium with 50 mg/mL bovine
pituitary extract and 5 ng/mL recombinant human epidermal
growth factor (EGF) (Invitrogen). MDA-PCa-2B cells were
maintained in BRFF-HPC1 media from AthenaES (Sapphire
Biosciences) supplemented with 20% FCS. All media was supple-
mented with 50 U/mL penicillin G and 50 mg/mL streptomycin
(CSL Biosciences). For steroid treatment experiments, cells were
cultured until z70% confluent, and then maintained in media
containing 10% charcoal-stripped serum (HyClone) for 48 h
followed by the addition of 1 nM R1881.
Microarray analyses
cDNA was prepared and end-labeled using the 3DNA Array 350
kit (Genisphere) from RNA isolated from both LNCaP cells
treated with 1 nM R1881 for 48 h and an untreated ethanol
vehicle control. The cDNA was hybridized to 244K Agilent CGH
arrays—arrays that are normally used to detect anomalies at the
DNA level but used here to detect random transcription across the
genome. Agilent’s two-color microarray-based gene expression
protocol was followed using Agilent hybridization and wash
buffers, scanner, and feature extraction software. The raw data
from three independent experiments were processed with the
LIMMA Bioconductor package (Smyth 2004) using quantile
between-array normalization. A Bayesian-adjusted t-statistic from
a linear model built using LIMMA was used to determine
differential expression between R1881 treated and untreated
samples. Benjamini-Hochberg multiple test correction was used
to control for a false discovery rate of 10%.
RNA extraction, cDNA synthesis, and RT-PCR
Total RNA was extracted from cells using TRI-Reagent (Sigma
Chemical Co.) according to the manufacturer’s protocol and
treated with DNase I (Invitrogen). Complementary DNA (cDNA)
was synthesized from 2 mg of total RNA using SuperScript III
Reverse Transcriptase (Invitrogen), and random hexamers (Pro-
ligo) or gene/strand-specific primers targeting the KLK4 and b2-
microglobulin genes (Supplemental Table 1). In some experiments,
a synthetic linker sequence was conjugated to gene/strand-specific
primers for use in the RT as indicated. The cDNA was treated with
1 U of RNase H (Invitrogen) for 20 min at 37°C prior to use in
PCR. For nested PCR experiments, 1 mL of the first-round PCR
was used as template DNA for the second-round PCR.
59 and 39 RNA ligase–mediated rapid amplification
of cDNA ends (RLM-RACE)
RNA was extracted as per RT-PCR from cells after 24 h of
treatment with 1 nM R1881 with an additional purification of the
RNA through an RNeasy column (QIAGEN). An amount of 10 mg
(59) and 1 mg (39) of total RNA was used in RLM-RACE
(FirstChoice RLM-RACE kit; Ambion) as per the manufacturer’s
instructions, except Superscript III (instead of AMV) reverse
transcriptase was used for cDNA synthesis. The 59 RACE outer
and Ex5S-1 (first-round PCR), and 59 RACE inner and Ex5S-2
(second round PCR) primers were used for 59-RLM-RACE. The
39 RACE outer and Ex5AS or Ex2S (first-round PCR), and 39
RACE inner and Ex5AS-1 or Ex2S (second-round PCR) primers
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were used in 39 RACE. All primer sequences are detailed in
Supplemental Table 1. PCR amplicons were cloned into the
pGEMT easy vector (Promega), and clones were sequenced at
the Australia Genome Research Facility, University of Queensland,
Brisbane, Australia.
Northern blot analysis
LNCaP cells were cultured in 5% charcoal/dextran stripped FBS
(CSS) for 48 h followed by 48 h of treatment with either 1 nM
R1881 or vehicle control (ethanol). Total RNA was extracted using
the MirVana RNA Isolation kit (Ambion), and subsequent
poly(A) RNA was isolated using the poly(A) purist kit (Ambion).
Northern blots were carried out using standard techniques.
Briefly, 10 mg of poly(A) RNA was resolved on 1% agarose-
formaldehyde denaturing gels, transferred to Hybond-N mem-
branes (GE Healthcare) by capillary action using 103 SSC (1.5 M
NaCl, 0.15 M sodium citrate at pH 7.0) and cross-linked by UV
irradiation. Membranes were prehybridized for 1 h at 68°C, then
hybridized to an [a-32P]-labeled riboprobe targeting the KLK4
antisense 39 UTR using the Ultrahyb hybridization buffer
(Ambion) overnight at 68°C. Blots were washed according to
the Ultrahyb protocol (Ambion) and imaged by either autoradi-
ography or PhosphorImaging. Riboprobes were generated by in
vitro transcription as described (Maniatis et al. 1982) using a DNA
template prepared by introducing the T7 RNA polymerase pro-
moter upstream of a 45-mer derived from the microarray probe
sequence used to detect the KLK4 antisense transcript: (59-
AACAGATATTCCTGAATTCCTTCCGCAGGATGTATTTGGGG
GTCA-39). The PCR primers (T7 KLK4 39 UTR and T7 KLK4 L)
are detailed in Supplemental Table 1. KLK4 antisense bands were
normalized to b-Actin by reprobing the blots using a probe
generated by primer extension. The b-Actin labeling template was
generated from LNCaP cDNA using primers AC1 and AC2
(Supplemental Table 1). KLK4 antisense blots were then reprobed
for b-Actin using probes generated by primer extension using
primer AC2.
Genome-wide analysis of sense–antisense chimeras
in prostate cancer cells
Identification of further instances of sense–antisense chimeras was
performed using a recently published RNA-seq data set from
prostate cancer cells (LNCaP) after DHT or mock treatment (Li
et al. 2008). As well as the relevant biological context of these data
to the current study, this data set was selected for analysis because,
unlike many other RNA-seq data sets, contained only strand-
specific tags that had been stringently filtered to omit artifacts of
strand switching by reverse transcriptase during cDNA library
preparation (Perocchi et al. 2007). To identify sense-chimeric
transcripts within this data set, an index of all possible sense–
antisense exon–exon junctions within a 10-kb region (upstream
and downstream) for all mouse RefSeq genes (as at October 2009)
was built. That is, for each RefSeq gene, sequences were built
comprising every combination of the last 30 nt of each exon (39
end) paired with first 30 nt (59 end) of every exon of any antisense
transcript (as defined by UCSC all mRNA and all EST tracks)
within 10 kb of the gene (Supplemental Fig. 4). This library of
combinations was then interrogated for exact matching tags from
the RNA-seq data set using ZOOM (Lin et al. 2008). RNA-seq tags
that mapped exactly to either the genome or conventional splice
junctions had been omitted from the set. To determine the
minimum number of nucleotides that a tag must span across
the sense–antisense exon–exon junction, a control analysis exactly
as described above was performed, except that the pairing of
RefSeq exons with antisense mRNA/EST exons was randomized,
such that RefSeq exons could be paired with any mRNA/EST exon
throughout the genome. This approach has the advantage that
it provides an empirical basis upon which to determine the
threshold exon–exon junction overlap, where a mapped tag re-
presented the presence of a real transcript rather than a chance
mapping event and did not require any assumptions to be made
regarding variable nucleotide frequencies across the genome and
sequencing error rates in the RNA-seq tags. RNA-seq tags in-
dicative of sense–antisense chimeras could then be detected using
this empirically determined threshold. Finally, to confirm the
presence of these chimeric transcripts, mouse cDNA sequence
databases were queried with the identified sequences of the sense–
antisense exon–exon junctions.
In silico analyses of the KLK4 antisense promoter
Retrotransposon elements were identified using the RepeatMasker
track on the UCSC Genome Browser, March 2006 (hg18)
assembly (http://genome.ucsc.edu). TSSs were predicted using
the Neural Network Promoter Prediction software from the
Berkeley Drosophila Genome Project (http://www.fruitfly.org/
seq_tools/promoter.html). Transcriptional regulatory element
clusters were predicted using the Cis-element Cluster Finder,
CISTER algorithm (http://zlab.bu.edu/zmfrith/cister.shtml).
Transfection and luciferase reporter assays
LNCaP genomic DNA was used as template to generate three
deletion constructs encompassing 3357 bp of the KLK4 antisense
promoter beginning at 234 bp from the MSR1 repeat. SacI and
HindIII restriction sites were added to the primers to facilitate
orientation-specific cloning into the pGL3-Basic vector (Promega).
Forward (F5, F6, and F7) and reverse (2ASR-Hind III) primers
are detailed in Supplemental Table 1. The KLK4 promoter inserts
were amplified using high-fidelity platinum Taq (Invitrogen) and
subcloned into the pGEM-T Easy vector prior to cloning into
pGL3-Basic. All constructs were sequenced as described above.
KLK4 luciferase promoter constructs are designated in the Results
section according to their corresponding forward primer name.
22Rv1 cells were seeded in 24-well plates, and culture medium
was changed to antibiotic-free RPMI 1640, supplemented with
10% FCS (basal media) for 48 h prior to transfection. Transient
transfection of pGL3-Basic, F5-Luc, F6-Luc, and F7-Luc was
carried out at equimolar amounts equivalent to 0.5 mg of
K4.2875-Luc (Lai et al. 2009) using 2 mL of Lipofectamine 2000/
well (Invitrogen). Renilla (0.3 mg) was used as an internal control
for transfection efficiency. After 6 h of transfection, media was
replaced with basal media for a further 24 h. Luciferase activity was
measured using the Dual-Luciferase Reporter Assay System
(Promega) on a PolarStar plate reader (BMG; Labtech). Data are
expressed as luciferase activity normalized to Renilla activity and
represented as the standard error of the mean (SEM) from three
independent treatments that were each carried out in triplicate.
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SUPPLEMENTAL MATERIAL
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